Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum

Synaptic oligomeric tau in Alzheimer’s disease — A potential culprit in the spread of tau pathology through the brain

(2023) Martí Colom-Cadena et al.   NEURON

Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia

(2023) Shreyasee Das et al.   Alzheimers Research & Therapy

Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [ 11 C]UCB‐J

(2022) Adam P. Mecca et al.   Alzheimers & Dementia

Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration

(2022) Alba Cervantes González et al.   Molecular Neurodegeneration

Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease

(2022) Pia Kivisäkk et al.   Alzheimers Research & Therapy

Microtubule assembly by tau impairs endocytosis and neurotransmission via dynamin sequestration in Alzheimer’s disease synapse model

(2022) Tetsuya Hori et al.   eLife

P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles

(2022) Kirsten E. J. Wesenhagen et al.   Alzheimers Research & Therapy

Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease

(2022) Johanna Nilsson et al.   Alzheimers Research & Therapy

Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders

(2022) Johanna Nilsson et al.   Alzheimers & Dementia

CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study

(2021) Marta Milà-Alomà et al.   NEUROLOGY

VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome

(2021) Alberto Lleó et al.   Alzheimers Research & Therapy

An atlas of the protein-coding genes in the human, pig, and mouse brain

(2020) Evelina Sjöstedt et al.   SCIENCE

Amyloid-β Peptides Disrupt Interactions Between VAMP-2 and SNAP-25 in Neuronal Cells as Determined by FRET/FLIM

(2020) Nidhi Sharda et al.   JOURNAL OF ALZHEIMERS DISEASE

Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0

(2020) Nathalie Percie du Sert et al.   PLOS BIOLOGY

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays

(2020) Annika Öhrfelt et al.   Alzheimers Research & Therapy

Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid

(2019) Alberto Lleó et al.   MOLECULAR & CELLULAR PROTEOMICS

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease

(2019) Nicholas J. Ashton et al.   Science Advances

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse

(2019) Daniel Alcolea et al.   Annals of Clinical and Translational Neurology

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts

(2018) Rachel F. Buckley et al.   Alzheimers & Dementia

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease

(2018) Flora H. Duits et al.   Alzheimers Research & Therapy

Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging

(2018) Ming-Kai Chen et al.   JAMA Neurology

Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology

(2018) Åsa Sandelius et al.   Alzheimers & Dementia

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

(2018) Philip Scheltens et al.   Alzheimers Research & Therapy

Tau association with synaptic vesicles causes presynaptic dysfunction

(2017) Lujia Zhou et al.   Nature Communications

Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability

(2016) Martijn C. de Wilde et al.   Alzheimers & Dementia

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease

(2016) Annika Öhrfelt et al.   Alzheimers Research & Therapy

C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease

(2015) Ann De Vos et al.   Alzheimers & Dementia

Postsynaptic VAMP/Synaptobrevin Facilitates Differential Vesicle Trafficking of GluA1 and GluA2 AMPA Receptor Subunits

(2015) Suleman Hussain et al.   PLoS One

Amyloid-β Oligomers May Impair SNARE-Mediated Exocytosis by Direct Binding to Syntaxin 1a

(2015) Yoosoo Yang et al.   Cell Reports

A Practical Guide to Immunoassay Method Validation

(2015) Ulf Andreasson et al.   Frontiers in Neurology

Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins

(2014) B. G. Wilhelm et al.   SCIENCE

Measuring cognitive change in subjects with prodromal Alzheimer's disease

(2013) T. Mura et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease

(2012) Nicole C. Berchtold et al.   NEUROBIOLOGY OF AGING

Proteasome Inhibition Alleviates SNARE-Dependent Neurodegeneration

(2012) M. Sharma et al.   Science Translational Medicine

Revised criteria for diagnosis of Alzheimer’s disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease

(2011) Zaven S. Khachaturian   Alzheimers & Dementia

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

VAMP-2, SNAP-25A/B and syntaxin-1 in glutamatergic and GABAergic synapses of the rat cerebellar cortex

(2011) Vincenzo Benagiano et al.   BMC NEUROSCIENCE